Adashek, Jacob J.
Breunig, Joshua J.
Posadas, Edwin
Bhowmick, Neil A.
Ellis, Leigh
Freedland, Stephen J.
Kim, Hyung
Figlin, Robert
Gong, Jun http://orcid.org/0000-0001-8713-1406
Funding for this research was provided by:
U.S. Department of Defense (KC200178)
Article History
Accepted: 29 January 2022
First Online: 17 February 2022
Declarations
:
: No external funding was used in the preparation of this manuscript. U.S. Department of Defense (Grant no. KC200178).
: Edwin Posadas: Consulting or Advisory Role—CytoLumina, Genentech/Roche, Janssen Oncology, Janssen Oncology, Novartis; Speakers’ Bureau—Bayer; Research Funding—Pfizer; Patents, Royalties, Other Intellectual Property—Patent on NanoVelcro Assay for CTCs in prostate cancer; Travel, Accommodations, Expenses—TRACON Pharma. Neil Bhowmick: Leadership—Kairos Pharma Lmt., Armida Labs, Inc. Consulting: TRACON Pharma., Cellgene, Xencor. Research funding: Xencor. Stephen Freedland: Consulting or Advisory Role—Merck, Astellas, AstraZeneca, Pfizer, Janssen, Bayer, Clovis, Sanofi, Myovant, and Exact Sciences. Robert Figlin: Leadership—4Dx, Apollomics; Consulting or Advisory Role—Bristol-Myers Squibb, CBT Pharmaceuticals, Johnson & Johnson; Research Funding—Bristol-Myers Squibb (Inst), Calithera Biosciences (Inst), Exelixis (Inst), Merck (Inst), Peloton Therapeutics (Inst). Jun Gong: Consultant or Advisory Role—EMD Serono, Elsevier, Exelixis, QED Therapeutics, Natera, Basilea, HalioDx, Eisai, Janssen, Astellas and Amgen. All other authors report no other conflicts of interest in this work. JJB, RF, JG are supported by DoD KCRP Award KC200178.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: JG conceptualized the review; JA and JG wrote the initial drafts; all authors edited and approved the final version of the manuscript.